110 results about "Squamous Cell Cancers" patented technology

The present invention relates to immunoconjugates specific for human EPH receptor A5 (EphA5), methods of treatment of cancers (e.g., carcinomas including squamous cell carcinoma, and colorectal cancer) using said immunoconjugates, and related pharmaceutical compositions of said immunoconjugates.

The invention belongs to the technical field of biological medicine, and provides self-assembled polypeptide targeting mitochondria, a preparation method and application of the self-assembled polypeptide, a self-assembled polypeptide microneedle patch and a preparation method of the self-assembled polypeptide microneedle patch. According to the self-assembly polypeptide of the targeted mitochondria, the amino acid sequence is GFFGKXRXKXRX, and X represents cyclohexyl alanine. A targeting peptide (Mito) sequence KXRXKXRX can recognize cell mitochondria in a targeting manner, a self-assembly sequence GFFG is introduced to an N terminal of the Mito sequence KXRXKXRX, and the targeting peptide sequence is endowed with a self-assembly capability, so that the self-assembly polypeptide can cause morphological function abnormality of mitochondria in tumor cells, the tumor cells are killed, and inhibition of the tumor cells is realized. The self-assembled polypeptide disclosed by the invention is applied to treatment of tumor cells through in-situ administration of the self-assembled polypeptide microneedle patch. Oral squamous cell carcinoma serves as a highly proliferated tumor cell, rapid proliferation of the oral squamous cell carcinoma needs a large amount of energy supply for mitochondria, and therefore attacking of the mitochondria can serve as an effective treatment target.

The application discloses a photosensitizer conjugate for targeted treatment of tongue squamous cell carcinoma and a preparation method and application thereof, and belongs to the technical field of biological medicines. A novel PROTAC-PDT conjugate Gef-PRO-SS-TPE is synthesized, and the compound connects a PROTAC molecule Gef-PRO targeting EGFR and an AIE photosensitizer TPE derivative through a breakable disulfide bond. On one hand, Gef-PRO can specifically degrade EGFR and block tumor cell proliferation signals; on the other hand, the TPE derivative can generate ROS under light conditions and induce cell apoptosis. More importantly, the disulfide bond can be broken in response to high concentrations of glutathione (GSH) in tumor cells, realizing controllable release of Gef-PRO and TPE molecules, so as to exert a synergistic anti-tumor effect.

To provide anti-New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen-binding proteins and methods of using the same.SOLUTION: The present disclosure provides antigen-binding proteins that specifically bind to an HLA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5, or more amino acids.SELECTED DRAWING: None

The present invention relates to a method of predicting the vulnerability of a squamous cell carcinoma (SCC) to inhibition by a PI3K inhibitor, preferably by a PI3K / mTOR inhibitor, including the selection of the patient predicted to benefit from therapeutic administration with the PI3K inhibitor, preferably of the PI3K / mTOR inhibitor. Moreover, the present invention relates to a method of treating a squamous cell carcinoma (SCC) of a mammal, preferably a human patient, comprising administering a therapeutically effective amount of a PI3K inhibitor, preferably a therapeutically effective amount of a PI3K / mTOR inhibitor to said mammal, preferably said human patient. Furthermore, the present invention relates to pharmaceutical compositions and kits associated with the inventive methods.

The invention relates to the technical field of microorganisms, and particularly discloses a product for predicting tumor cell occurrence and metastasis risks and treating tumors by using a microbial marker. The cancers related to the invention comprise colon adenocarcinoma, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, hepatocellular carcinoma, lung squamous cell carcinoma, prostate adenocarcinoma, gastric adenocarcinoma, thyroid carcinoma, breast invasive carcinoma, uveal melanoma, esophageal carcinoma and the like. As a marker for predicting the occurrence and metastasis risk of tumor cells. The invention also screens specific microorganisms of healthy tissues relative to tumor tissues as potential means for treating tumors. The screened flora marker is high in sensitivity and good in specificity, and a new method is provided for tumor cell generation and metastasis monitoring and tumor treatment.

The present disclosure provides anti-ULBP2 antibodies or antigen binding fragments thereof, including bispecific. The antibodies are administered in combination with a chemotherapy agent, a radiation therapy, and / or an immune checkpoint inhibitor for treatment of basal squamous cancer. The present disclosure also relates to methods and kits for detecting a predisposition to, determining the risk of, and guiding therapy for ULBP2 related disorders.

The invention relates to application of WDR74 and / or ALYREF as molecular targets in esophageal squamous cell carcinoma diagnosis and treatment, and belongs to the technical field of biological medicine. Aiming at the problem that the esophageal squamous cell carcinoma lacks an effective targeted treatment means, the invention discovers that the expression quantity of WDR74 in tumor tissues is obviously higher than that in para-carcinoma tissues, and the high expression of WDR74 prompts poor prognosis of a patient, and reveals that WDR74 protein and ALYREF protein have specific binding, and the mRNA stability of EGFR is enhanced through ALYREF-mediated m5C RNA epigenetic modification, so that STAT3 phosphorylation is activated, and the treatment effect of the esophageal squamous cell carcinoma is enhanced. Further, the STAT3 is combined with the promoter region of the apoptosis-inhibiting gene MCL1, and finally cell apoptosis is inhibited and tumor formation is promoted. The invention provides a new molecular target and a solution for developing a WDR74 and ALYREF targeting medicine for treating esophageal squamous cell carcinoma and related diagnosis and prognosis evaluation products.

The invention relates to application of lactobacillus muricatum in preparation of a medicine for treating oral cancer, the oral cancer is oral squamous cell carcinoma, a C57BL / 6 mouse tongue squamous cell carcinoma model induced by a 4-NQO water drinking method and a C3H / HeN subcutaneous tumor model inoculated by SCC7 tumor cells are constructed, and the lactobacillus muricatum has a remarkable inhibition effect on the oral cancer; experiments prove that the number / area / volume / weight of tumors is remarkably reduced by the lactobacillus muricatum, tumor marginal infiltration and abnormal karyokinesis are effectively inhibited, the expression quantity of tumor proliferation markers is remarkably reduced, and obvious pathological changes do not appear in main organs (heart, liver, spleen, lung and kidney) of mice. The method for minimally invasive injection of the lactobacillus muricatum into the oral squamous cell cancer tumor is safe, drug resistance is not easily induced, the treatment scheme is standardized, and the method has good clinical application potential.

The present disclosure relates to methods for predicting the risk of recurrence and / or metastasis, or both in primary cutaneous squamous cell carcinoma (cSCC).

The present disclosure relates to detecting one or more types of oropharyngeal cancer in a biological sample from a subject. In particular, the present disclosure provides compositions and methods for detecting the presence or absence of one or more types of oropharyngeal cancer (e.g., HPV+ oropharyngeal squamous cell cancer) in a biological sample from a subject having or suspected of having an oropharyngeal cancer.

The present disclosure provides antigen-binding proteins that specifically bind to an H LA-displayed New York esophageal squamous cell carcinoma 1 (NY-ESO-1) peptide, and therapeutic and diagnostic methods of using those binding proteins. The antigen-binding proteins of the present disclosure bind with a high degree of specificity to HLA-displayed NY-ESO-1 and do not bind to HLA-displayed peptides that differ by 2, 3, 4, 5 or more amino acids.

The application provides an oxazinane compound, a preparation method, a pharmaceutical composition and application, and a general formula of the oxazinane compound or a pharmaceutically acceptable salt thereof is shown as formula (I). The oxazinane compound has obvious proliferation inhibition effect on cancer cells, especially human head and neck squamous cell carcinoma cell strains HSC4, HSC3, HSC2, CAL33, SCC4 and human glioma cell strain U251, can block the cell cycle, effectively inhibit the phosphorylation level of key proteins in the PI3K / AKT / mTOR pathway at the molecular level, has the potential to be prepared into a new antitumor drug, and has a good market prospect.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention relates to a methylation site marker for assisting in early diagnosis of esophageal squamous cell carcinoma and application of the methylation site marker, and belongs to the technical field of biomedicine. The methylation site marker is one or a combination of human peripheral blood mononuclear cell methylation sites cg05064044, cg03395511 and cg21548813, and the nucleotide sequence of the methylation site marker is as shown in SEQ ID NO. 1-3. According to the present invention, the methylation chip detection results show that the methylation levels of the cg05064044, the cg03395511 and the cg21548813 in the peripheral blood mononuclear cells of the esophageal squamous cell carcinoma patient are significantly increased compared to the health control group; the methylation levels of cg05064044, cg03395511 and cg21548813 sites in PBMC of esophageal squamous cell carcinoma patients in a training queue and a verification queue are all obviously higher than those of a healthy control group through further analysis. Finally, through ROC curve analysis, it is determined that the three methylation sites cg05064044, cg03395511 and cg21548813 have good specificity and sensitivity, have high diagnosis efficiency when being independently or jointly used for esophageal squamous cell carcinoma diagnosis and can be used as potential molecular markers for esophageal squamous cell carcinoma diagnosis.

The invention relates to a computer-implemented method for detecting oesophageal squamous cell dysplasia (OSCD) or oesophageal squamous cell cancer (OSCC) in a cell sample from a subject. This invention also relates to a computer-implemented method for generating a trained model to detect OSCD or OSCC. This invention also relates to a computer-readable storage medium or a computer program comprising instructions which when executed by a computer, are capable of causing the computer to perform the method. This invention also relates to a kit comprising the computer program or computer-readable storage medium and a non-endoscopic cell collection device. The invention also relates to an apparatus for performing the method. The invention further relates to the use of genome wide instability scores (GWIS) as a diagnostic marker for cancer, wherein GWIS is a measure of the CNV across a plurality of autosomal arms in a cell sample from a subject.

The present disclosure relates to a novel method of treating squamous cell carcinoma (SCC), and in particular head and neck squamous cell carcinoma (HSSCC) and cutaneous carcinoma (CC) using MUC1-C inhibitors. Also described herein is a novel method of suppressing the progression of premalignant lesions to a squamous cell carcinoma.

The invention belongs to the technical field of medicines, and particularly discloses an oral squamous cell carcinoma inhibitor and application thereof. The inhibitor takes rutin as an active component. In-vitro experiments prove that rutin can significantly inhibit proliferation, clone formation, migration and invasion ability of OSCC cells in a dose-dependent manner, and effectively induce cell apoptosis. The action mechanism of the rutin is as follows: the rutin can directly target STAT3 protein and inhibit phosphorylation of the STAT3 protein so as to regulate and control a downstream BCL2 / CASP3 apoptosis pathway, thereby playing a role in treating OSCC. Molecular docking results further show that rutin and STAT3 have strong binding capacity. The invention discloses a new application of rutin as an STAT3 inhibitor in treating oral squamous cell carcinoma, and provides a new strategy and a candidate compound for developing high-efficiency and low-toxicity OSCC treatment medicines.

This invention discloses a method and system for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma, belonging to the field of two-dimensional image processing technology for oral squamous cell carcinoma. It aims to improve the accuracy and stability of early screening for oral squamous cell carcinoma. The invention acquires oral image data, labels the acquired images according to pre-set classification standards to obtain training and testing sets; preprocesses the oral image data to obtain preprocessed training and testing sets; performs data augmentation on the oral image data in the training set to obtain a data-augmented training set; constructs an image feature extraction model based on a convolutional neural network; and trains the convolutional neural network-based image feature extraction model using supervised learning to obtain a trained convolutional neural network-based image feature extraction model for two-dimensional image segmentation and benign / malignant differentiation of oral squamous cell carcinoma.

The invention relates to the technical field of medical detection. The invention aims to provide a nano-probe for detecting the expression of an epidermal growth factor receptor of head and neck squamous carcinoma cells. The nano-probe is a nano-particle with a core-shell structure, the nano particle takes a nano Au particle as a core, and 4-mercaptobenzoic acid (4-MBA) is adsorbed on the surface of the Au core as a Raman signal internal reference molecule; according to the nanoparticle, SiO2 is used as a shell, and PEG and EGFR antibodies are linked to the SiO2 shell. According to the nanoprobe, head and neck squamous cell cancer cell and tissue imaging is researched by adopting a surface enhanced Raman spectroscopy technology, tumor cell and tissue EGFR expression images are drawn, and quantitative analysis and research are carried out. A rapid, visual and accurate new tool is provided for clinically detecting the squamous cell carcinoma of the head and neck and the EGFR expression condition of the squamous cell carcinoma of the head and neck.

The present invention relates to the field of oncology. It more particularly relates to a method for evaluating the prognosis or the response to a therapeutic treatment of a subject having a squamous cell carcinoma by assessing the multinucleated giant cells status of a SCC tumor of the subject. This method may be advantageously computer-implemented for ease of use in the clinic.

The present application relates to the technical field of squamous cell carcinoma early diagnosis, and provides a method for assisting early diagnosis of head and neck squamous cell carcinoma, comprising: S1: collecting existing video data obtained by using MET targeted near-infrared fluorescence imaging technology, and training a supervised learning model by using the video data set; S2: building a classifier system, inputting video data to be classified into the classifier system, and applying the trained supervised learning model to segment and determine the pathological properties of the lesion; S3: comparing the efficiency of the built classifier system and human doctors in diagnosing early head and neck squamous cell carcinoma; S4: screening key features related to the occurrence and development of head and neck squamous cell carcinoma through the classifier system, forming a comprehensive data set by connecting the key features with multi-omics data, building an intermediate model based on the comprehensive data set, and performing bioinformatics analysis by using the intermediate model. The present application can improve the early detection rate of HNSCC, improve the accuracy of biopsy, and realize early and accurate tumor diagnosis.

There is provided the combination of Bacillus Calmette-Guérin (BCG) vaccine and β-glucan adjuvant for the treatment of a cancer characterized by the presence of protumoral T3 neutrophils in the tumour microenvironment. The β-glucan is characterized by a μ-1,3 glucose backbone. The BCG and β-glucan combination demonstrated a synergistic effect in remodeling the tumour microenvironment to resist conversion of neutrophils into the T3 phenotype. The cancer can be bladder cancer, melanoma, lung adenocarcinoma, head and neck squamous cell cancer, pancreatic adenocarcinoma, low-grade gliomas, esophageal carcinoma, and cervical squamous cell carcinoma.

The present invention relates to 1,2-dicarboxamide compounds of Formula (I); pharmaceutically acceptable salts, pharmaceutically acceptable stereoisomers, N-oxides or combination thereof, wherein 'X', 'Y', 'Z', ring A, ring B, R1, R2, R3, R4, R5, R6, 'm' and 'n' are as defined herein. The present invention also relates to 1,2-dicarboxamide compounds that modulate cellular activities like proliferation, differentiation, adhesion, migration and apoptosis by modulating protein kinase enzymatic activity. In particular the invention relates to compounds which inhibit, regulate, and / or modulate tyrosine kinases such as FLT1 (VEGFR1), FLT4 (VEGFR3), KDR (VEGFR2), MET (C-Met), MERTK (c-Mer), RET, AXL, TEK (TIE 2) and EGFR. The present disclosure relates to 1,2-dicarboxamide compounds for use in modulating kinase enzymatic activity and accordingly modulating kinase-dependent associated diseases and conditions such as cancers like Thyroid carcinoma, Ovarian carcinoma, Pancreatic carcinoma, Prostatic carcinoma, Renal cell carcinoma, Hepatocellular carcinoma, Breast carcinoma, Colorectal carcinoma, Oral squamous cell carcinoma, Colorectal, Lung adenocarcinoma or Endometrial cancer.

The application relates to application of FLVCR2-AS1 as a biomarker and therapeutic target of oral squamous cell carcinoma, and belongs to the technical field of biological medicine. The application provides application of FLVCR2-AS1 as a biomarker in preparation of a product for diagnosing oral squamous cell carcinoma, wherein the nucleotide sequence of the FLVCR2-AS1 is shown in SEQ ID NO:1. It is found and identified in the application that FLVCR2-AS1 is specifically lowly expressed in oral squamous cell carcinoma tissues and cell lines, and the expression level is significantly related to the prognosis of patients. Further research finds that overexpression of FLVCR2-AS1 can effectively inhibit the migration and invasion ability of oral squamous cell carcinoma cells. These results prove that FLVCR2-AS1 is a novel molecular target with clinical application potential for oral squamous cell carcinoma.

This invention provides the use of CX6258 or its salts in medicaments for the prevention and / or treatment of lung cancer, belonging to the field of biomedicine. This invention is the first to discover that CX6258HCl can effectively inhibit the growth of lung squamous cell carcinoma cell lines and organoids, and that CX6258HCl can also be combined with cisplatin to treat lung squamous cell carcinoma. Therefore, CX6258 or its salts have broad application prospects in medicaments for the prevention and / or treatment of lung cancer, especially lung squamous cell carcinoma.

A C1QBP protein can be used in preparation for an oral cancer screening or prognosis marker. A reagent for detecting a C1QBP protein expression level is in preparation for an oral cancer screening or prognosis kit. The C1QBP protein expression level in an oral mucosa tissue of a patient suffering from oral squamous cell carcinoma is found to be remarkably higher than that of a healthy patient. Using a reagent for detecting a C1QBP protein expression level for preparing a screening or prognosis kit of oral squamous cell carcinoma can realize effective screening or prognosis of oral squamous cell carcinoma.

The invention relates to the technical field of chemical medicines. The invention provides application of butenol in preparation of a medicine for treating skin squamous cell carcinoma. The invention also provides a butein-containing medicine for treating skin squamous cell carcinoma. According to the invention, butein can inhibit the growth of cSCC cells and reduce the migration ability of the cSCC cells; meanwhile, the protein expression levels of key proteins TWEAK, Fn14 and cIAP1 in tumors can be inhibited.

Based on chloroauric acid and a cobalt precursor, through the synergistic effect of a stabilizer and a chiral ligand, the chiral gold-cobalt nano particle with the multi-layer structure is successfully constructed. The nanoparticles show excellent physical and chemical characteristics under the selection of metal elements and the regulation and control of ligands. Through the synergistic effect of gold and cobalt, the magnetism of the material is enhanced, the material is endowed with unique optical characteristics, and meanwhile, the material has special biocompatibility and stability due to introduction of a chiral ligand. Particularly, in treatment of oral squamous cell carcinoma, by virtue of excellent magnetic and optical properties, the magnetic nano-material can effectively target a tumor site and improve the treatment effect, and a novel, efficient and safe treatment strategy is provided for treatment of oral squamous cell carcinoma. The novel chiral gold-cobalt nanoparticles are expected to play an important role in the field of cancer treatment, especially in targeted therapy and imaging diagnosis.

The invention provides application of an EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for treating diseases mediated by the activity of a guanylate exchange factor (GEF) or jointly mediated by the activity of the guanylate exchange factor (GEF) and the activity of EGFR tyrosine kinase. The diseases are cancers selected from the following groups: lung cancer, colon cancer, breast cancer, endometrial cancer, thyroid cancer, glioma, squamous cell carcinoma, prostate cancer, melanoma, leukemia and glioblastoma. Specifically, the invention discovers that EGFR has a GEF function for promoting activation of Ras homologous protein (Rhb) besides traditional tyrosine kinase activity, the function does not depend on the tyrosine kinase activity and plays a key role by depending on a glutamic acid residue at the 804th site on an EGFR molecule, the Rhb-GEF activity of EGFR causes allosteric activation of a mammal rapamycin target protein complex 1 (mTORC1), and the activity of the EGFR causes allosteric activation of the mammal rapamycin target protein complex 1 (mTORC1). The tumor growth is finally promoted.